4u Created
Image default

BioNTech executive says it is too early to predict China vaccine approval By Reuters


© Reuters. FILE PHOTO: Syringes are seen in front of a displayed Biontech logo in this illustration taken November 10, 2020. REUTERS/Dado Ruvic/Illustration

FRANKFURT (Reuters) – A BioNTech executive on Monday confirmed that the company is in discussions with Chinese authorities over regulatory approval of the German biotech firm’s COVID-19 vaccine for use by expatriates in China but the outcome was uncertain.

“We have seen some positive re-engagement, as has been reported. We confirm that we have been taking part in some discussions, which are very positive,” Chief Strategy Officer Ryan Richardson said in an analyst call.

He added it was too early to predict the extent or the timing of such an approval for foreigners working in China.

BioNTech shares rose on Friday after German Chancellor Olaf Scholz announced an agreement to let expatriates in China use the vaccine and he pressed for Beijing to allow the shot to be made freely available to Chinese citizens.


Source link

Related posts

Shenzhou International Group Holdings Ltd PT Raised to HK$111 at JPMorgan

India stocks lower at close of trade; Nifty 50 down 1.94% By Investing.com

Philippines airport scrambles to restore normalcy after power cut By Reuters